Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.46 |
| ▸ | CNR2 | P34972 | 13/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254998 | 0.90 | RAB9A (0.42) | CNR1CNR2POLBRAB9AFKBP1A | |
| SCHEMBL3187098 | 0.87 | CNR1 (0.46) | CNR1CNR2POLBRAB9AMAPT | |
| SCHEMBL3188631 | 0.86 | CNR1 (0.45) | CNR1CNR2POLBRAB9AFKBP1A | |
| SCHEMBL3204049 | 0.86 | CNR1 (0.41) | CNR1CNR2POLBRAB9AFKBP1A | |
| SCHEMBL3199174 | 0.86 | CNR1 (0.42) | CNR1CNR2POLBRAB9AFKBP1A | |
| SCHEMBL3189107 | 0.84 | CNR1 (0.40) | CNR1CNR2POLBRAB9AFKBP1A | |
| SCHEMBL3198111 | 0.84 | ALDH1A1 (0.41) | CNR1CNR2POLBRAB9AMAPT | |
| SCHEMBL3198812 | 0.83 | CNR1 (0.44) | CNR1CNR2POLBRAB9AFKBP1A | |
| SCHEMBL13255036 | 0.82 | CNR1 (0.38) | CNR1CNR2POLBRAB9AALDH1A1 | |
| SCHEMBL3197647 | 0.82 | ACE2 (0.39) | CNR1CNR2POLBRAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | claimed |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-20060074086-A1 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074086-A1 | Phenyl derivatives and methods of use | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885POLB 3506/4885 |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885POLB 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.